Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.

Tuberculin positivity in Kawasaki disease: an unusual occurrence.

Dysregulation of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in advanced retinoblastoma.

DNA repair in cancer: emerging targets for personalized therapy.

Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy.

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.

Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas.

The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.

Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?

Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.

Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma.